RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer

Author:

Miao Chenkui12ORCID,Tsujino Takuya13ORCID,Takai Tomoaki13,Gui Fu1ORCID,Tsutsumi Takeshi13ORCID,Sztupinszki Zsofia4ORCID,Wang Zengjun2,Azuma Haruhito3,Szallasi Zoltan4ORCID,Mouw Kent W.5ORCID,Zou Lee6ORCID,Kibel Adam S.1ORCID,Jia Li1ORCID

Affiliation:

1. Division of Urology, Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA.

2. Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

3. Department of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan.

4. Computational Health Informatics Program, Boston Children’s Hospital, Boston, MA, USA.

5. Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA.

6. Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Abstract

Current targeted cancer therapies are largely guided by mutations of a single gene, which overlooks concurrent genomic alterations. Here, we show that RNASEH2B , RB1 , and BRCA2 , three closely located genes on chromosome 13q, are frequently deleted in prostate cancer individually or jointly. Loss of RNASEH2B confers cancer cells sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition due to impaired ribonucleotide excision repair and PARP trapping. When co-deleted with RB1 , however, cells lose their sensitivity, in part, through E2F1-induced BRCA2 expression, thereby enhancing homologous recombination repair capacity. Nevertheless, loss of BRCA2 resensitizes RNASEH2B/RB1 co-deleted cells to PARP inhibition. Our results may explain some of the disparate clinical results from PARP inhibition due to interaction between multiple genomic alterations and support a comprehensive genomic test to determine who may benefit from PARP inhibition. Last, we show that ATR inhibition can disrupt E2F1-induced BRCA2 expression and overcome PARP inhibitor resistance caused by RB1 loss.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3